Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company developing engineered T-cell therapies for cancers and autoimmune diseases. Its ARTEMIS® platform is designed to regulate T-cell activation through mechanisms resembling the natural T-cell receptor. The lead candidate, EB103, is a… From the company’s description.
In fiscal 2025, Estrella Immunopharma, Inc. reported a net loss of $13.06M. Operations used $1.79M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Estrella Immunopharma, Inc. does
In the company’s own words
Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company developing engineered T-cell therapies for cancers and autoimmune diseases. Its ARTEMIS® platform is designed to regulate T-cell activation through mechanisms resembling the natural T-cell receptor. The lead candidate, EB103, is a CD19-directed therapy being evaluated in a Phase I/II trial for relapsed or refractory B-cell non-Hodgkin lymphoma; EB104 is a preclinical dual-targeting candidate for CD19- and CD22-positive blood cancers. The company is also exploring EB103 with Imugene’s CF33-CD19t oncolytic virus as a “mark and kill” approach for solid tumors, and EB201 for systemic lupus erythematosus. Estrella’s programs rely on an exclusive ARTEMIS platform license from Eureka Therapeutics, which also provides research, development and manufacturing services. The company’s business is focused on research and development rather than commercial product sales, and it reports no operating segments in the supplied business description. Its website is https://estrellabio.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- EMERYVILLE, CA
- Fiscal year end
- December
- CIK
- 1844417
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Estrella Immunopharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Estrella Immunopharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Estrella Immunopharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Estrella Immunopharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Estrella Immunopharma, Inc.'s last four quarterly filings that the numbers alone won't show?”